ABUS vs HBIO vs ITRN vs REPL

For growth investors, Arbutus Biopharma Corporation (ABUS) is the stronger pick with 128.

2% revenue growth year-over-year, versus -8. 1% for Harvard Bioscience, Inc. (HBIO). Ituran Location and Control Ltd. (ITRN) offers the better valuation at 20. 2x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Arbutus Biopharma Corporation (ABUS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ituran Location and Control Ltd.

(ITRN) delivered a total return of +180. 2%, compared to -90. 7% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: ITRN returned +233. 6% versus REPL's -78. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Replimune Group, Inc.

(REPL) is the lower-risk stock at 0. 83β versus Harvard Bioscience, Inc. 's 2. 03β — meaning HBIO is approximately 144% more volatile than REPL relative to the S&P 500. On balance sheet safety, Arbutus Biopharma Corporation (ABUS) carries a lower debt/equity ratio of 1% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arbutus Biopharma Corporation (ABUS) is pulling ahead at 128.

2% versus -8. 1% for Harvard Bioscience, Inc. (HBIO). On earnings-per-share growth, the picture is similar: Arbutus Biopharma Corporation grew EPS 55. 3% year-over-year, compared to -357. 1% for Harvard Bioscience, Inc.. Over a 3-year CAGR, ITRN leads at 7. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ituran Location and Control Ltd.

(ITRN) is the more profitable company, earning 16. 1% net margin versus -237. 9% for Arbutus Biopharma Corporation — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ITRN leads at 21. 4% versus -271. 0% for ABUS. At the gross margin level — before operating expenses — HBIO leads at 53. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for REPL: 274.

3% to $12. 50.

In this comparison, ITRN (3.

2% yield) pays a dividend. ABUS, HBIO, REPL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ituran Location and Control Ltd.

(ITRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 18), 3. 2% yield, +233. 6% 10Y return). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ITRN: +233. 6%, HBIO: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ABUS (Healthcare) and HBIO (Healthcare) and ITRN (Technology) and REPL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ABUS is a small-cap high-growth stock; HBIO is a small-cap quality compounder stock; ITRN is a small-cap income-oriented stock; REPL is a small-cap quality compounder stock. ITRN pays a dividend while ABUS, HBIO, REPL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.